Ifosfamide Inclusion.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Primary Mediastinal Large B-Cell Lymphoma
Primary Mediastinal Large B-Cell Lymphoma Page 1 of 13 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. Note: Consider Clinical Trials as treatment options for eligible patients. PATHOLOGIC DIAGNOSIS INITIAL EVALUATION ESSENTIAL: 5 ● Physical exam: attention to node-bearing areas, including Waldeyer's ring, ESSENTIAL: and to size of liver and spleen ● ECOG performance status ● Hematopathology review of all slides with at least one paraffin ● B symptoms (Unexplained fever >38°C during the previous month; block or 15 unstained slides representative of the tumor. Rebiopsy if Recurrent drenching night sweats during the previous month; Weight consult material is nondiagnostic. loss >10 percent of body weight ≤ 6 months of diagnosis) ● Adequate morphology and immunophenotyping to establish 1 ● CBC with differential, LDH, BUN, creatinine, albumin, AST, diagnosis ALT, total bilirubin, alkaline phosphatase, serum calcium, uric acid ○ Paraffin Panel: CD3, CD20 and/or another pan-B-cell marker ● Beta 2 microglobulin (CD19, PAX-5, CD79a) or ● Screening for HIV 1 and 2, hepatitis B and C (HBcAb, HBsAg, HCV -
©Ferrata Storti Foundation
Malignant Lymphomas Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and research paper mobilizing therapy for haematologica 2002; 87:816-821 relapsed/refractory lymphoma http://www.haematologica.ws/2002_08/816.htm patients PIER LUIGI ZINZANI, MONICA TANI, ANNA LIA MOLINARI,* VITTORIO STEFONI, ELIANA ZUFFA,* LAPO ALINARI, ANNALISA GABRIELE, FRANCESCA BONIFAZI, Institute of Hematology and Medical Oncology PATRIZIA ALBERTINI, MARZIA SALVUCCI,* SANTE TURA, “L. e A. Seràgnoli”, University of Bologna; MICHELE BACCARANI *Division of Hematology, Ravenna Hospital, Ravenna, Italy Background and Objectives. Therapy for relapsed/refrac- lthough advanced stage Hodgkin’s disease tory lymphomas should be based only on drugs not (HD) and some aggressive non-Hodgkin’s included in the front-line chemotherapy regimens. We Alymphomas (NHL) are potentially curable adopted the strategy of using salvage chemotherapy to with standard chemotherapy, many patients either debulk disease and simultaneously mobilize stem cells, relapse or never achieve remission.1,2 One way of using a regimen based on ifosfamide and etoposide, improving this situation could be to intensify (drugs not usually used for front-line treatment). front-line chemotherapy, either by dose-escala- tion of conventional therapy3 or by adding high- Design and Methods. A three-drug combination of ifos- famide, epirubicin and etoposide (IEV) was used to treat dose chemotherapy with peripheral blood stem cell 4,5 62 patients with relapsing or refractory aggressive non- (PBSC) rescue. Whereas treatment of relapsing Hodgkin’s lymphoma (NHL; n=51) or Hodgkin’s disease disease with conventional chemo- and/or radiation (HD; n=11). Forty-five of the patients were studied for the therapy is unsatisfactory, especially in those feasibility of peripheral blood stem cell (PBSC) harvest. -
Hodgkin Lymphoma Treatment Regimens
HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Classical Hodgkin Lymphoma1 Note: All recommendations are Category 2A unless otherwise indicated. Primary Treatment Stage IA, IIA Favorable (No Bulky Disease, <3 Sites of Disease, ESR <50, and No E-lesions) REGIMEN DOSING Doxorubicin + Bleomycin + Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + Vinblastine + Dacarbazine vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over (ABVD) (Category 1)2-5 60 minutes. -
(Rituxan®), Rituximab-Abbs (Truxima®), Rituximab-Pvvr (Ruxience®) Prior Authorization Drug Coverage Policy
1 Rituximab Products: Rituximab (Rituxan®), Rituximab-abbs (Truxima®), Rituximab-pvvr (Ruxience®) Prior Authorization Drug Coverage Policy Effective Date: 2/1/2021 Revision Date: n/a Review Date: 7/2/20 Lines of Business: Commercial Policy type: Prior Authorization This Drug Coverage Policy provides parameters for the coverage of rituximab (Rituxan®), rituximab-abbs (Truxima®), and rituximab-pvvr (Ruxience®). Consideration of medically necessary indications are based upon U.S. Food and Drug Administration (FDA) indications, recommended uses within the Centers of Medicare & Medicaid Services (CMS) five recognized compendia, including the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium (Category 1 or 2A recommendations), and peer-reviewed scientific literature eligible for coverage according to the CMS, Medicare Benefit Policy Manual, Chapter 15, section 50.4.5 titled, “Off- Label Use of Anti-Cancer Drugs and Biologics.” This policy evaluates whether the drug therapy is proven to be effective based on published evidence-based medicine. Drug Description1-3 Rituximab (Rituxan®), rituximab-abbs (Truxima®), and rituximab-pvvr (Ruxience®) are monoclonal antibodies that target the CD20 antigen expressed on the surface of pre-B and mature B- lymphocytes. Upon binding to cluster of differentiation (CD) 20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC). B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. -
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’S Lymphomas Version 2.2015
NCCN Guidelines Index NHL Table of Contents Discussion NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’s Lymphomas Version 2.2015 NCCN.org Continue Version 2.2015, 03/03/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® . Peripheral T-Cell Lymphomas NCCN Guidelines Version 2.2015 NCCN Guidelines Index NHL Table of Contents Peripheral T-Cell Lymphomas Discussion DIAGNOSIS SUBTYPES ESSENTIAL: · Review of all slides with at least one paraffin block representative of the tumor should be done by a hematopathologist with expertise in the diagnosis of PTCL. Rebiopsy if consult material is nondiagnostic. · An FNA alone is not sufficient for the initial diagnosis of peripheral T-cell lymphoma. Subtypes included: · Adequate immunophenotyping to establish diagnosisa,b · Peripheral T-cell lymphoma (PTCL), NOS > IHC panel: CD20, CD3, CD10, BCL6, Ki-67, CD5, CD30, CD2, · Angioimmunoblastic T-cell lymphoma (AITL)d See Workup CD4, CD8, CD7, CD56, CD57 CD21, CD23, EBER-ISH, ALK · Anaplastic large cell lymphoma (ALCL), ALK positive (TCEL-2) or · ALCL, ALK negative > Cell surface marker analysis by flow cytometry: · Enteropathy-associated T-cell lymphoma (EATL) kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20, CD30, CD4, CD8, CD7, CD2; TCRαβ; TCRγ Subtypesnot included: · Primary cutaneous ALCL USEFUL UNDER CERTAIN CIRCUMSTANCES: · All other T-cell lymphomas · Molecular analysis to detect: antigen receptor gene rearrangements; t(2;5) and variants · Additional immunohistochemical studies to establish Extranodal NK/T-cell lymphoma, nasal type (See NKTL-1) lymphoma subtype:βγ F1, TCR-C M1, CD279/PD1, CXCL-13 · Cytogenetics to establish clonality · Assessment of HTLV-1c serology in at-risk populations. -
Drug Resistance in Non-Hodgkin Lymphomas
International Journal of Molecular Sciences Review Drug Resistance in Non-Hodgkin Lymphomas Pavel Klener 1,2,* and Magdalena Klanova 1,2 1 First Department of Internale Medicine-Hematology, University General Hospital in Prague, 128 08 Prague, Czech Republic; [email protected] 2 Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, 128 53 Prague, Czech Republic * Correspondence: [email protected] or [email protected] Received: 3 February 2020; Accepted: 15 March 2020; Published: 18 March 2020 Abstract: Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of malignant transformation of mature lymphocytes during various stages of differentiation. The WHO classification of NHL recognizes more than 90 nosological units with peculiar pathophysiology and prognosis. Since the end of the 20th century, our increasing knowledge of the molecular biology of lymphoma subtypes led to the identification of novel druggable targets and subsequent testing and clinical approval of novel anti-lymphoma agents, which translated into significant improvement of patients’ outcome. Despite immense progress, our effort to control or even eradicate malignant lymphoma clones has been frequently hampered by the development of drug resistance with ensuing unmet medical need to cope with relapsed or treatment-refractory disease. A better understanding of the molecular mechanisms that underlie inherent or acquired drug resistance might lead to the design of more effective front-line treatment algorithms based on reliable predictive markers or personalized salvage therapy, tailored to overcome resistant clones, by targeting weak spots of lymphoma cells resistant to previous line(s) of therapy. This review focuses on the history and recent advances in our understanding of molecular mechanisms of resistance to genotoxic and targeted agents used in clinical practice for the therapy of NHL. -
Effectiveness of Rituximab-Containing Treatment Regimens in Idiopathic Multicentric Castleman Disease
Annals of Hematology https://doi.org/10.1007/s00277-018-3347-0 ORIGINAL ARTICLE Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease Yujun Dong1 & Lu Zhang2 & Lin Nong 3 & Lihong Wang1 & Zeyin Liang1 & Daobin Zhou2 & David C. Fajgenbaum4 & Hanyun Ren1 & Jian Li2 Received: 27 February 2018 /Accepted: 23 April 2018 # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract Human herpes virus type 8 (HHV-8)-negative, idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disease often involving constitutional symptoms, cytopenias, and multiple organ system dysfunction. In China, the majority of MCD cases are HHV-8 negative. Given that siltuximab, the only FDA-approved treatment for iMCD is not available in China; rituximab- and cyclophosphamide-containing regimens are often used in the treatment of Chinese iMCD patients. To evaluate the efficacy of rituximab in this rare and heterogeneous disease, clinical and pathological data from 27 cases of iMCD were retrospectively analyzed from two large medical centers in China. The novel diagnostic criteria for iMCD were applied, and POEMS syndrome, IgG4-related diseases, and follicular dendritic cell sarcomas cases were excluded from analyses. Total response rate of rituximab- and cyclophosphamide-containing regimens was 55.5%, with 33.3% (9/27) of the cases reaching CR and 22.2% (6/27) PR. In the 14 cases of R-R iMCD, total response rate was only 42.9% (CR 14.3% [2/14], PR 28.6% [4/14]). The 5-year OS of these 27 iMCD cases was 81% (95% CI 64–98; 27 total patients, 4 events, 23 censored) after receiving these regimens, but the 5-year PFS was 43% (95% CI 19–66; 25 total patients, 11 events, 14 censored). -
PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’S Disease
PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease Lale Kostakoglu, MD1; Morton Coleman, MD2; John P. Leonard, MD2; Ichiei Kuji, MD1; Holly Zoe1; and Stanley J. Goldsmith, MD1 1Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York; and 2Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Department of Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York Early identification of chemotherapy-refractory lymphoma patients Accurate evaluation of response to therapy is of vital provides a basis for alternative treatment strategies. Metabolic imag- importance in the management of patients with lymphoma 18 ing with F-FDG PET offers functional tissue characterization that is (1). The main endpoint of chemotherapy is the achievement useful for assessing response to therapy. Our objective was to deter- mine the predictive value of 18F-FDG PET early during chemotherapy of complete remission, which is associated with a longer (after 1 cycle) and at the completion of chemotherapy for subsequent progression-free survival (PFS) and potential cure than is progression-free survival (PFS) in patients with aggressive non- partial remission (2). The definition of complete remission, Hodgkin’s lymphoma (NHL) or Hodgkin’s disease (HD). Methods: however, is usually based on anatomic imaging modalities 18F-FDG PET (dual-head coincidence camera with attenuation cor- that may be unable to differentiate viable tumor from post- rection) was performed before and after 1 cycle of chemotherapy on therapy changes such as scarring or fibrosis. -
High-Dose Mitoxantrone + Melphalan (MITO/L-PAM)
Leukemia (2001) 15, 256–263 2001 Nature Publishing Group All rights reserved 0887-6924/01 $15.00 www.nature.com/leu High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity C Tarella1, F Zallio1, D Caracciolo1, A Cuttica1, P Corradini1,2, P Gavarotti1, M Ladetto1, V Podio3, A Sargiotto4, G Rossi5, AM Gianni6 and A Pileri1 1Dipartimento di Medicina e Oncologia Sperimentale, Divisione Universitaria di Ematologia; Serv. 3Univ. e 4Osped di Medicina Nucleare; 5Divisione Universitaria di Radioterapia-Azienda Ospedaliera S Giovanni Battista di Torino, Torino; and 6Unita` Trapianto Midollo, Ist Naz. Tumori, Milano, Italy Hematological and extrahematological toxicity of high-dose The ease deriving from the excellent tolerability of PBPC (hd) mitoxantrone (MITO) and melphalan (L-PAM) as condition- procedures probably slowed down the efforts aimed to look ing regimen prior to peripheral blood progenitor cell (PBPC) autograft was evaluated in 113 lymphoma patients (87 at dis- for innovative and possibly more effective conditioning regi- ease onset). Autograft was the final part of a hd-sequential mens. In fact, most autograft programs employed nowadays (HDS) chemotherapy program, including a debulkying phase are based on conditioning regimens designed several years (1–2 APO ± 2 DHAP courses) and then sequential adminis- ago, such as TBI + cyclophosphamide (CY), or regimens con- tration of hd-cyclophosphamide, methotrexate (or Ara-C) and taining nitrosurea or melphalan (L-PAM), such as BEAM, CBV etoposide, at 10 to 30 day intervals. Autograft phase included: or BEAC.17–21 Looking for a better conditioning regimen, one (1) hd-MITO, given at 60 mg/m2 on day −5; (2) hd-L-PAM, given at 180 mg/m2 on day −2; (3) PBPC autograft, with a median of should not only consider the antitumor activity of a given drug 11 × 106 CD341/kg, or 70 × 104 CFU-GM/kg, on day 0. -
Ifosfamide and Etoposide-Based Chemotherapy As Salvage and Mobilizing Regimens for Poor Prognosis Lymphoma
Bone Marrow Transplantation, (1999) 23, 413–419 1999 Stockton Press All rights reserved 0268–3369/99 $12.00 http://www.stockton-press.co.uk/bmt Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma J Mayer1, Z Korˇ´ıstek1,IVa´sˇova´1, J Vorlι´cˇek1 and P Vodva´rˇka2 1Department of Internal Medicine – Hematooncology, Masaryk University Hospital, Brno; and 2Department of Radiotherapeutic Medicine, Faculty Hospital, Ostrava, Czech Republic Summary: Growth factors (G-CSF or GM-CSF, granulocyte or gra- nulocyte–macrophage colony-stimulating factors) and/or a We treated 40 patients with poor prognosis lymphomas. higher dose of cyclophosphamide are standard for adequate Patients with non-Hodgkin’s lymphoma (NHL, n = 14) mobilization of PBSC, although other combinations of received MINE chemotherapy (mesna, ifosfamide polychemotherapy and growth factors can be used. A com- 1330 mg/m2 and etoposide 65 mg/m2 by i.v. infusions on bination of chemotherapy and growth factors is more effec- days 1–3, mitoxantrone 8 mg/m2 i.v. on day 1), and those tive than growth factors and chemotherapy alone and inten- with Hodgkin’s disease (HD, n = 26) received VIM sity of chemotherapy correlates with the degree of PBSC chemotherapy (mesna, ifosfamide 1200 mg/m2 by i.v. mobilization.3–8 In lymphoma patients, PBSC can be mobil- infusion on days 1–5, etoposide 90 mg/m2 by i.v. infusion ized with growth factors alone or by a combination of high- on days 1, 3 and 5, and methotrexate 30 mg/m2 i.v. on dose cyclophosphamide and growth factors, but these regi- days 1 and 5). -
Acronyms for Oncology Regimens
ACRONYMS AND ABBREVIATIONS OF COMMONLY USED REGIMENS ACRONYM CHEMOTHERAPY COMBINATION 7 + 3 Anthracycline (daunorubicin/idarubicin) or anthracenedione (mitoxantrone)/cytarabine ABV Doxorubicin/ bleomycin/vincristine ABVD Doxorubicin/ bleomycin/vinblastine/dacarbazine AC Doxorubicin/cyclophosphamide ACE Doxorubicin/cyclophosphamide/etoposide AI Doxorubicin/ifosfamide AIDA Tretinoin/idarubicin/dexamethasone/mitoxantrone/6-mercaptopurine/ methotrexate AP Doxorubicin/cisplatin AT Doxorubicin/docetaxel BEACOPP Bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/ prednisone BEP Bleomycin/etoposide/cisplatin BMC Bleomycin/methotrexate/carmustine CAD Cyclophosphamide/doxorubicin/dacarbazine CAP Cyclophosphamide/doxorubicin/cisplatin CAPIRI Capecitabine/irinotecan CAPOX Capecitabine/oxaliplatin CAV Cyclophosphamide/doxorubicin/vincristine CDE Cyclophosphamide/doxorubicin/etoposide CDE-R Cyclophsopahmide/doxorubicin/etoposide/rituximab CECA Cyclophosphamide/etoposide/carboplatin/cytarabine CFAR Alemtuzumab/fludarabine/cyclophosphamide/rituximab CHOEP Cyclophosphamide/doxorubicin/vincristine/etoposide/prednisone CHOP Cyclophosphamide/doxorubicin/vincristine/prednisone CHOP-R Cyclophosphamide/doxorubicin/vincristine/prednisone/rtuximab ChlVPP Chlorambucil/vinblastine/procarbazine/prednisone CMF Cyclophosphamide/methotrexate/5-Fluorouracil CNOP Cyclophosphamide/mitoxantrone/vincristine/prednisone CODOX-M Cyclophsopahmide/vincristine/doxorubicin/cyclophosphamide/methotrexate/ leucovorin/intrathecal cytarabine/intrathecal methotrexate -
Poor Mobilization Is an Independent Prognostic Factor in Patients with Malignant Lymphomas Treated by Peripheral Blood Stem Cell Transplantation
Bone Marrow Transplantation (2006) 37, 719–724 & 2006 Nature Publishing Group All rights reserved 0268-3369/06 $30.00 www.nature.com/bmt ORIGINAL ARTICLE Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation V Pavone1,2, F Gaudio1, G Console3, U Vitolo4, P Iacopino3, A Guarini1, V Liso1, T Perrone1 and A Liso5 1Hematology Department, University of Bari, Bari, Italy; 2Hematology Department, Hospital ‘C Panico’, Tricase, Italy; 3Bone Marrow Transplantation Unit, Reggio Calabria, Italy; 4Haematology Department, Turin Hospital, Turin, Italy and 5Hematology Unit, University of Foggia, Foggia, Italy Haemopoietic stem cell therapy is an increasingly adopted ment frequently employed in relapsed malignant lympho- procedure in the treatment of patients with malignant mas (ML) or in very high-risk ML.2–12 The presence of lymphoma. In this retrospective analysis, we evaluated HSCs in peripheral blood is usually extremely low before 262 patients, 57 (22%) with Hodgkin’s and 205 (78%) mobilizing procedures, and engraftment of CD34 þ per- with non-Hodgkin’s lymphomas (NHL), and 665 harvest- ipheral blood stem cells (PBSC) depends on the infusion of ing procedures in order to assess the impact of poor an adequate number of CD34 þ stem cells to restore mobilization on survival and to determine the factors that haemopoiesis.13–23 Indeed, the number of CD34 þ cells is may be predictive of CD34 þ poor mobilization. The commonly used to predict the potential engraftment of mobilization chemotherapy regimens consisted of high- harvested HSC.17,19,22,23 A cutoff of 20CD34 þ cells/mlin dose cyclophosphamide in 92 patients (35.1%) and a high- the peripheral blood has been arbitrarily defined to predict dose cytarabine-containing regimen (DHAP in 87 patients a successful collection procedure, and an infusion of a –(33.2%), MAD in 83 (31.7%)).